Dr. Reddy’s

Dr. Reddy’s Laboratories has launched a generic version of a widely prescribed eye drop in the United States, marking a strategic expansion of its ophthalmology portfolio. The move underscores the company’s focus on high-growth therapeutic segments and its commitment to providing affordable alternatives in regulated markets. Analysts highlight that entry into the US generic ophthalmic market enhances revenue diversification, leverages regulatory approvals, and positions Dr. Reddy’s to capture market share in a specialized segment.

Indian pharmaceutical equities plunged on June 17, as investor sentiment deteriorated following US President Donald Trump’s renewed threat to impose tariffs on pharmaceutical imports. The Nifty Pharma index dropped over 2%, marking it as the day’s worst-performing sector. With India being one of the largest exporters of generic drugs to the US, analysts fear a significant impact on margins, revenues, and forward guidance for key industry players. Major firms like Cipla, Dr.